Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2017 /
Edoxaban versus dalteparin for venous thromboembolism associated with cancer

9th - 12th Dec 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.12.17
Views: 2235
Rating:

Dr Harry Büller - University of Amsterdam, Amsterdam, Netherlands

Dr Büller speaks with ecancer at the 2017 ASH annual meeting about a randomised, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/edoxaban versus dalteparin for venous thromboembolism associated with cancer. 

He details the balance of disease recurrence and bleeding in trial groups, noting the improved treatment adherence among those taking a daily pill in place of subcutaneous injection, and the planned sensitivity assessments for the trial.

Overall, Dr Büller describes these results as practice-changing, and encourages doctors and patients to consider their use.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content. 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation